New Search

If you are not happy with the results below please do another search

1 search result for:

1

SOTIO expands its Antibody-Drug Conjugate pipeline with exclusive collaboration and license agreement with LegoChem Biosciences

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced an exclusive, target-specific license and option agreement with LegoChem Biosciences, a biotechnology company focused on developing its clinical-stage platform technology enabling antibody-drug conjugates (ADCs) with an excellent therapeutic index. SOTIO will obtain rights to deploy LCB’s ADC technology for up to five therapeutic […]